An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab
| Autor: | Danielle Degenne, Gilles Paintaud, Nicolas Ceze, Hervé Watier, Etienne Dorval, Nicolas Azzopardi, Friedrich Piller, Thierry Lecomte, David Ternant |
|---|---|
| Přispěvatelé: | Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Centre de biophysique moléculaire (CBM), Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Service de cancérologie digestive, Université de Tours, Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Université de Tours (UT), Frapart, Isabelle |
| Rok vydání: | 2009 |
| Předmět: |
Male
IRINOTECAN Colorectal cancer [SDV]Life Sciences [q-bio] Cetuximab Pharmacology 030226 pharmacology & pharmacy 0302 clinical medicine Limit of Detection Pharmacology (medical) Epidermal growth factor receptor education.field_of_study biology medicine.diagnostic_test Antibodies Monoclonal C225 Middle Aged 3. Good health [SDV] Life Sciences [q-bio] Dose–response relationship Chemotherapy Adjuvant Head and Neck Neoplasms [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology 030220 oncology & carcinogenesis Monoclonal Female Drug Monitoring Colorectal Neoplasms pharmacokinetics medicine.drug Adult Metabolic Clearance Rate Population Enzyme-Linked Immunosorbent Assay Antibodies Monoclonal Humanized 03 medical and health sciences Pharmacokinetics medicine Humans COMBINATION education Aged business.industry tuximab medicine.disease ANTIBODY Therapeutic drug monitoring Immunoglobulin G Immunology [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology biology.protein GROWTH-FACTOR RECEPTOR business |
| Zdroj: | Ther. Drug Monit. Ther. Drug Monit., 2009, 31 (5), pp.597-601 Therapeutic Drug Monitoring Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2009, 31 (5), pp.597-601 |
| ISSN: | 0163-4356 |
| Popis: | International audience; Cetuximab is anti-epidermal growth factor receptor monoclonal antibody used in the treatment of colorectal and head and neck cancers. Part of the interindividual differences in response may be explained by interindividual variability in pharmacokinetics. An assay measuring cetuximab serum concentrations is therefore needed. An enzyme-linked immunosorbent assay was developed using microtiter plates sensitized with a recombinant human epidermal growth factor receptor extracellular domain. Lower and upper limits of quantitation and limit of detection were determined. Eight standard calibrators (SCs) and 3 quality controls (QCs), that is, 0.75, 7.5, and 15 mg/L, were tested on 5 occasions on 1 day and on 5 occasions on different days. Trough and peak serum concentrations of cetuximab were measured in 15 patients with metastatic colorectal cancer and I patient with undetermined neoplasia undergoing cetuximab-based chemotherapy. Cetuximab concentrations were described using a 2-compartment population pharmacokinetic model. Imprecision and accuracy of SC and QC were |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|